DK0808367T3 - Vaskulære slimhindeaddressiner samt anvendelse deraf - Google Patents

Vaskulære slimhindeaddressiner samt anvendelse deraf

Info

Publication number: DK0808367T3
Authority: DK; Denmark
Prior art keywords: madcam; primate; recombinant; proteins; relates
Prior art date: 1995-02-10

Application number

DK96906504T

Other languages

Danish (da)

English (en)

Inventor

Michael J Briskin

Douglas J Ringler

Dominic Picarella

Walter Newman

Original Assignee

Millennium Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-10

Filing date

1996-02-12

Publication date

2007-11-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27011628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0808367(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-02-10 Priority claimed from US08/386,857 external-priority patent/US6551593B1/en

1995-09-01 Priority claimed from US08/523,004 external-priority patent/US7750137B2/en

1996-02-12 Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc

2007-11-05 Application granted granted Critical

2007-11-05 Publication of DK0808367T3 publication Critical patent/DK0808367T3/da

Links

230000002792 vascular Effects 0.000 title 1
241000288906 Primates Species 0.000 abstract 5
102000039446 nucleic acids Human genes 0.000 abstract 4
108020004707 nucleic acids Proteins 0.000 abstract 4
150000007523 nucleic acids Chemical class 0.000 abstract 4
210000000265 leukocyte Anatomy 0.000 abstract 3
210000004027 cell Anatomy 0.000 abstract 2
210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
108091005461 Nucleic proteins Proteins 0.000 abstract 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
210000003038 endothelium Anatomy 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000007115 recruitment Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
210000001519 tissue Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
External Artificial Organs (AREA)

DK96906504T 1995-02-10 1996-02-12 Vaskulære slimhindeaddressiner samt anvendelse deraf DK0808367T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/386,857 US6551593B1 (en)	1995-02-10	1995-02-10	Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US08/523,004 US7750137B2 (en)	1995-09-01	1995-09-01	Mucosal vascular addressins
PCT/US1996/002153 WO1996024673A1 (en)	1995-02-10	1996-02-12	Mucosal vascular addressins and uses thereof

Publications (1)

Publication Number	Publication Date
DK0808367T3 true DK0808367T3 (da)	2007-11-05

Family

ID=27011628

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96906504T DK0808367T3 (da)	1995-02-10	1996-02-12	Vaskulære slimhindeaddressiner samt anvendelse deraf

Country Status (12)

Country	Link
EP (1)	EP0808367B1 (de)
JP (1)	JP4205162B2 (de)
AT (1)	ATE366809T1 (de)
AU (1)	AU4986296A (de)
CA (1)	CA2212702C (de)
DE (1)	DE69637155T2 (de)
DK (1)	DK0808367T3 (de)
ES (1)	ES2290955T3 (de)
MX (1)	MX9706049A (de)
NZ (1)	NZ303523A (de)
PT (1)	PT808367E (de)
WO (1)	WO1996024673A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0948597A4 (de) *	1996-11-01	2002-07-10	Human Genome Sciences Inc	Menschliches, Schleimhaut-spezifisches Addressin-Zelladhäsionsmolekül (MAdCAM-1) und dessen Spleissvarianten
AU7348798A (en) *	1997-05-09	1998-12-08	John P. Robarts Research Institute, The	Method for dislodging infiltrated leukocytes from a tissue
WO1999058573A1 (en) *	1998-05-13	1999-11-18	Genentech, Inc.	Diagnosis and treatment of hepatic disorders
AU2007201698B2 (en) *	1998-05-13	2011-10-13	Genentech, Inc.	Diagnosis and treatment of hepatic disorders
US7090845B2 (en)	1998-05-13	2006-08-15	Genentech, Inc.	Diagnosis and treatment of hepatic disorders
AUPR524101A0 (en)	2001-05-25	2001-06-21	Council Of The Queensland Institute Of Medical Research, The	Antigen targeting
WO2003047526A2 (en) *	2001-11-30	2003-06-12	Incyte Genomics, Inc.	Cell adhesion and extracellular matrix proteins
US20070202097A1 (en) *	2003-03-10	2007-08-30	Krissansen Geoffrey W	Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
DE602004030565D1 (de) *	2003-05-01	2011-01-27	Scripps Research Inst	Selektive r-cadherin-antagonisten und verfahren
MX370489B (es) *	2004-01-09	2019-12-16	Pfizer	Anticuerpos contra madcam.
WO2006026759A2 (en)	2004-09-03	2006-03-09	Genentech, Inc.	Humanized anti-beta7 antagonists and uses therefor
EP1904531B1 (de) *	2005-07-08	2010-10-06	Pfizer Limited	Madcam-antikörper
WO2007007152A2 (en) *	2005-07-11	2007-01-18	Pfizer Limited	Anti-madcam antibodies to treat metastatic cancers and chloroma
KR101361905B1 (ko) *	2008-05-16	2014-02-21	제넨테크, 인크.	베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
MX367097B (es)	2011-05-02	2019-08-05	Millennium Pharm Inc	FORMULACION PARA ANTICUERPO ANTI-A4ß7.
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2016086147A1 (en)	2014-11-26	2016-06-02	Millennium Pharmaceuticals, Inc.	Vedolizumab for the treatment of fistulizing crohn's disease
WO2016105572A1 (en)	2014-12-24	2016-06-30	Millennium Pharmaceuticals, Inc.	PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
MA41636A (fr)	2015-03-06	2018-01-09	Millennium Pharm Inc	Méthode de traitement de la cholangite sclérosante primitive
AU2017234010B2 (en)	2016-03-14	2024-06-13	Millennium Pharmaceuticals, Inc.	Methods of treating or preventing graft versus host disease
CA3017743A1 (en)	2016-03-14	2017-09-21	Millennium Pharmaceuticals, Inc.	Method of preventing graft versus host disease
JP7069032B2 (ja)	2016-03-24	2022-05-17	ミレニアムファーマシューティカルズ，インコーポレイテッド	がん免疫治療における胃腸の免疫関連有害事象の治療方法
WO2017165742A1 (en)	2016-03-24	2017-09-28	Millennium Pharmaceuticals, Inc.	Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
US10918716B2 (en)	2016-05-04	2021-02-16	Millennium Pharmaceuticals, Inc.	Triple combination therapy for treating Crohn's disease
EP3468597A1 (de)	2016-06-12	2019-04-17	Millennium Pharmaceuticals, Inc.	Verfahren zur behandlung von entzündlicher darmerkrankung
WO2018104893A1 (en)	2016-12-06	2018-06-14	Glaxosmithkline Intellectual Property Development Limited	Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
AU2018256840A1 (en)	2017-04-28	2019-11-07	Millennium Pharmaceuticals, Inc.	Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab)
EP3652211A1 (de)	2017-07-14	2020-05-20	Pfizer Inc.	Antikörper gegen madcam
BR112021023345A2 (pt) *	2019-05-20	2022-02-01	Pandion Operations Inc	Imunotolerância com alvo em madcam
WO2024249568A1 (en)	2023-05-30	2024-12-05	Paragon Therapeutics, Inc.	Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en)	2023-06-09	2024-12-12	Takeda Pharmaceutical Company Limited	Methods and compositions for treating ulcerative colitis
CN121889424A (zh)	2023-08-14	2026-04-17	派拉冈医疗公司	α4β7整联蛋白结合蛋白及使用方法
WO2026058045A1 (en)	2024-09-12	2026-03-19	Takeda Pharmaceutical Company Limited	Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU5675794A (en) *	1992-12-15	1994-07-04	Board Of Trustees Of The Leland Stanford Junior University	Mucosal vascular addressin, dna and expression

1996
- 1996-02-12 WO PCT/US1996/002153 patent/WO1996024673A1/en not_active Ceased
- 1996-02-12 DE DE69637155T patent/DE69637155T2/de not_active Expired - Lifetime
- 1996-02-12 MX MX9706049A patent/MX9706049A/es active IP Right Grant
- 1996-02-12 AU AU49862/96A patent/AU4986296A/en not_active Abandoned
- 1996-02-12 AT AT96906504T patent/ATE366809T1/de active
- 1996-02-12 NZ NZ303523A patent/NZ303523A/en not_active IP Right Cessation
- 1996-02-12 EP EP96906504A patent/EP0808367B1/de not_active Revoked
- 1996-02-12 CA CA2212702A patent/CA2212702C/en not_active Expired - Lifetime
- 1996-02-12 PT PT96906504T patent/PT808367E/pt unknown
- 1996-02-12 JP JP52449196A patent/JP4205162B2/ja not_active Expired - Fee Related
- 1996-02-12 DK DK96906504T patent/DK0808367T3/da active
- 1996-02-12 ES ES96906504T patent/ES2290955T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE69637155T2 (de)	2008-02-07
WO1996024673A1 (en)	1996-08-15
JP4205162B2 (ja)	2009-01-07
AU4986296A (en)	1996-08-27
JPH10513365A (ja)	1998-12-22
ES2290955T3 (es)	2008-02-16
CA2212702A1 (en)	1996-08-15
EP0808367A1 (de)	1997-11-26
PT808367E (pt)	2007-10-22
CA2212702C (en)	2010-04-20
MX9706049A (es)	1998-02-28
DE69637155D1 (de)	2007-08-23
EP0808367B1 (de)	2007-07-11
ATE366809T1 (de)	2007-08-15
NZ303523A (en)	2002-02-01

Publication	Publication Date	Title
DK0808367T3 (da)	2007-11-05	Vaskulære slimhindeaddressiner samt anvendelse deraf
Geiser et al.	1993	The interleukin-8-related chemotactic cytokines GRO alpha, GRO beta, and GRO gamma activate human neutrophil and basophil leukocytes
RU2734169C2 (ru)	2020-10-13	Способ получения повышающей регуляции экспрессии PD-L1, полипептиды, конъюгат, слитый полипептид, композиция и комбинация для обеспечения повышающей регуляции экспрессии PD-L1
Postlethwaite et al.	1981	Induction of fibroblast chemotaxis by fibronectin. Localization of the chemotactic region to a 140,000-molecular weight non-gelatin-binding fragment.
Pearse	1988	Receptors compete for adaptors found in plasma membrane coated pits.
DE60219611T2 (de)	2007-12-27	Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
US20060173162A1 (en)	2006-08-03	Bactericidak anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp)
KR100451446B1 (ko)	2004-10-06	아글리코 생성물 및 그의 사용 방법
JP2742925B2 (ja)	1998-04-22	血栓形成抑制用治療薬組成物
JP2512453B2 (ja)	1996-07-03	天然のコロニ−促進因子―１の精製
JP2004043502A (ja)	2004-02-12	新規蛋白質及びこれを使用した薬剤の製法
JPH08503490A (ja)	1996-04-16	リポ多糖結合性および中和能のあるペプチド
WO1996022371A3 (en)	1996-10-17	C-C CHEMOKINE RECEPTOR 3: CKP-3 OR Eos-L2
EP1399476B1 (de)	2006-08-16	Verwendung löslicher cytokeratin-1-fragmente in diagnostik
JPH03204896A (ja)	1991-09-06	インターフェロンレセプター細胞外断片
JP4794102B2 (ja)	2011-10-19	フィブリンのシトルリン誘導体及び慢性関節リウマチの診断又は治療のためのその使用
WO1994025476A1 (en)	1994-11-10	Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
HU226468B1 (en)	2008-12-29	Amino-terminally truncated mcp-2-as chemokine antagonists
EA009414B1 (ru)	2007-12-28	Терапевтические применения вариантов хемокинов
McNaughton et al.	2018	Novel anti-inflammatory peptides based on chemokine–glycosaminoglycan interactions reduce leukocyte migration and disease severity in a model of rheumatoid arthritis
Bond et al.	1993	Native and recombinant Fel dI as probes into the relationship of allergen structure to human IgE immunoreactivity
Campistol et al.	1996	Polymerization of normal and intact β2-microglobulin as the amyloidogenic protein in dialysis-amyloidosis
EP1683866B1 (de)	2017-03-01	Deletionsmutanten des IgE-abhängigen Histamin-Releasing-Faktor (HRF) mit der Fähigkeit zur Histaminfreisetzung, HRF-bindende Peptide sowie deren Verwendung
EP0698666B1 (de)	2006-04-26	Modifiziertes Epimorphin
CN111848780A (zh)	2020-10-30	一种IL-36的可溶性受体sIL-36R及其应用